These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 33359211)

  • 1. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
    Chen C; Xie L; Ren T; Huang Y; Xu J; Guo W
    Cancer Lett; 2021 Mar; 500():1-10. PubMed ID: 33359211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
    Liu R; Hu Y; Liu T; Wang Y
    BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances on immunotherapy for osteosarcoma.
    Yu S; Yao X
    Mol Cancer; 2024 Sep; 23(1):192. PubMed ID: 39245737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.
    Bozorgi A; Sabouri L
    Cancer Treat Res Commun; 2021; 27():100324. PubMed ID: 33517237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for osteosarcoma: Where do we go from here?
    Wedekind MF; Wagner LM; Cripe TP
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the effects of M2 macrophage-derived PDE4C on the prognosis, metastasis and immunotherapy benefit of osteosarcoma.
    Pan F; Pan R; Hu R; Zhang H; Lei S; Zhang L; Zhou C; Zeng Z; Tian X; Xie Q
    J Cell Mol Med; 2024 May; 28(10):e18395. PubMed ID: 38774995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
    Mason NJ
    Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential predictive value of immune-related genes FUCA1 and NCKAP1L for osteosarcoma metastasis.
    Wang X; Dou J; Liu M; Zhang Y; Li Y; Tong Z
    Gene; 2024 Nov; 927():148645. PubMed ID: 38844271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.
    Yu L; Zhang J; Li Y
    Front Immunol; 2022; 13():871076. PubMed ID: 36311748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and Emerging Targets in Immunotherapy for Osteosarcoma.
    Miwa S; Shirai T; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
    J Oncol; 2019; 2019():7035045. PubMed ID: 30693030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteosarcoma: current status of immunotherapy and future trends (Review).
    Mori K; Rédini F; Gouin F; Cherrier B; Heymann D
    Oncol Rep; 2006 Mar; 15(3):693-700. PubMed ID: 16465432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.
    Li Z; Dou P; Liu T; He S
    Cell Physiol Biochem; 2017; 42(4):1407-1419. PubMed ID: 28715796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomaterials-Boosted Immunotherapy for Osteosarcoma.
    Sun C; Li S; Ding J
    Adv Healthc Mater; 2024 Sep; 13(23):e2400864. PubMed ID: 38771618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
    Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
    Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
    [No Abstract]   [Full Text] [Related]  

  • 18. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma.
    Deng C; Xu Y; Fu J; Zhu X; Chen H; Xu H; Wang G; Song Y; Song G; Lu J; Liu R; Tang Q; Huang W; Wang J
    Cancer Sci; 2020 Jun; 111(6):1899-1909. PubMed ID: 32232912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.
    Li LQ; Zhang LH; Zhang Y; Lu XC; Zhang Y; Liu YK; Khader MA; Jia-Wen ; Tao-Liu ; Li JZ
    Aging (Albany NY); 2020 Nov; 12(22):22906-22926. PubMed ID: 33203792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.
    Wang Z; Li B; Ren Y; Ye Z
    Front Immunol; 2016; 7():353. PubMed ID: 27683579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.